Back to resultsSurgery Versus Radiotherapy for Locally Advanced Prostate Cancer (SPCG-15)
Primary Purpose
Prostatic Neoplasms
Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Prostatectomy/Surgery
Radiotherapy with adjuvant androgen deprivation therapy
Sponsored by
About this trial
This is an interventional treatment trial for Prostatic Neoplasms focused on measuring Prostatic neoplasms, Locally advanced, Radiotherapy, Surgery, Mortality
Eligibility Criteria
Inclusion Criteria:
- Age ≤75, at the time of randomization
- Diagnosed histopathologically confirmed and untreated prostatic adenocarcinoma
- The general condition and mental status of patients shall permit observation in accordance with the study protocol
- Tumor stage (T, M, N):
T3 stage (as indicated by digital rectal examination or MR imaging or other validated imaging technique) T4 tumors can be included if considered resectable/treatable on MR imaging Significant extra-capsular tumor extension in biopsy (rare but acceptable for inclusion) M0 (no sign of distant metastases) confirmed by bone scan or CT or MRT of axial skeleton (at a maximum of pelvis and lumbar vertebral column) N0 stage, defined in accordance to the RECIST guidelines as no sign of macroscopic retroperitoneal lymph-node metastases >=1.5 cm (short axis) on CT scan, PET-CT, or MRT or more than one suspected lymph-node metastases Presence Gleason grade pattern 4 or 5
- Signed Informed consent
Exclusion Criteria:
- Patients with a PSA value of > 100 ng/mL
- Any medical condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives Patients with contraindications for either prostatectomy or radiotherapy to the prostate are not eligible for the study. Most contraindications for these treatments are relative, but in general, radiotherapy may be precluded among patients with:
- Anorectal disease, such as fistulae, Crohn´s disease, and ulcerative colitis
- Significant obstructive lower urinary tract symptoms
- Proximal stricture of the urethrae
- Severe neurogenic bladder dysfunction
- Enlarged prostate beyond 70-90 ml
- Previous radiotherapy to the pelvic region
On the other hand, surgery may be precluded among patients with:
- Massive local tumor progression, particularly in the apical region
- Massive abdominal obesity
- Contraindications to anesthesia
Sites / Locations
- Aalborg University HospitalRecruiting
- Aarhus University HospitalRecruiting
- Rigshospitalet, Region h, Department OncologyRecruiting
- Rigshopsitalet Department urologyRecruiting
- Herlev HospitalRecruiting
- Odense University HospitalRecruiting
- Helsinki University Hospital, Department of UrologyRecruiting
- Tampere University Hospital, Pihlajalinna KoskiklinikkaRecruiting
- Turku University HospitalRecruiting
- Sørlandet HospitalRecruiting
- Oslo University Hospital, Department of radiation TherapyRecruiting
- Oslo University Hospital, Department UrologyRecruiting
- University Hospital of North NorwayRecruiting
- St. Olavs HospitalRecruiting
- Falu LasarettRecruiting
- Sahlgrenska University HospitalRecruiting
- Helsingborgs LasarettRecruiting
- Länssjukhuset RyhovRecruiting
- Kirurgkliniken, BlekingesjukhusetRecruiting
- Linköping University HospitalRecruiting
- Skåne University HospitalRecruiting
- Vrinevis Hospital
- Karolinska University HospitalRecruiting
- Capio St Göran HospitalRecruiting
- Sundvalls HospitalRecruiting
- Umeå University HospitalRecruiting
- Uppsala Akademiska HospitalRecruiting
- CentrallasarettetRecruiting
- Centrallasarettet Växjö HospitalRecruiting
- Östersund HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Prostatectomy/Surgery
Radiotherapy with adjuvant androgen deprivation therapy
Arm Description
Patients with locally advanced prostate adenocarcinoma recieves Prostatectomy/Surgery with or without adjuvant or salvage radiotherapy
Patients with locally advanced prostate adenocarcinoma treated with adjuvant androgen deprivation therapy
Outcomes
Primary Outcome Measures
Cause specific survival
Cause-specific survival (CSS) will be calculated as "1-cause specific mortality. Mortality and mortality causes will be ascertained from the nationwide Cause-of-Death Register. In the absence of a functioning Cause-of-Death register, an endpoint committee of at least 2 medical doctors will determine the cause of death.
Secondary Outcome Measures
Metastasis free survival
Composite endpoint of time to metastasis and survival
Quality of life - general psychological, urinary, bowel and sexual health
Questionnaire-based evaluation of general psychological health, urinary health, bowel health, and sexual health.
Questions about self Questions about quality of life in the past month (scale 1 to 7; 1=no quality, 7=the best quality) Depression and anxiety (scale 1 to 7; 1=no, 7=very) Symptom Form (EPIC-26) (scale 1 to 5; 1= no problem, 5=major problem) Questions about the urinary tract Questions about sexual function Questions about bowel function Questions about prostate cancer - diagnosis and treatment Questions about prostate cancer check-ups Questions about hormone/castration therapy and its significance Questions about pain and lymph swelling
Overall survival
Overall survival (OS) will be calculated as "1-overall mortality. Mortality data will be ascertained through the nationwide Cause-of-Death Register.
Time to castration-resistant prostate cancer
Ascertained at follow-up visits
Time to biochemical progression
Ascertained at follow-up visits
Adverse events
Ascertained at visits
Cardiovascular disease
Data from national PcBaSe-register (https://snd.gu.se/en/catalogue/study/ext0014), a registry where the national prostate cancer registry (NPCR, www.npcr.se) has been linked to the Swedish National Cancer Register, the Cause of Death Register, the Prescribed Drug Register, the National Patient Register, and the Acute Myocardial Infarction Register, the Register of the Total Population, the Longitudinal Integration database for health insurance and labour market studies (LISA), the Multi-Generatioon Register and several other population-based registers.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02102477
Brief Title
Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer
Acronym
SPCG-15
Official Title
Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 2014 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2045 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Olof Akre
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This prospective, open randomized phase III surgical trial seeks to study whether radical prostatectomy (with or without the combination of external radiation) improves prostate-cancer specific survival in comparison with primary radiation treatment and hormonal treatment among patients diagnosed with locally advanced (T3) prostate cancer. Untreated or conservatively treated locally advanced prostate cancer is associated with high mortality. Modern curative treatment for advanced solid malign tumors include surgery and/or radiation plus attempted chemotherapy if available to achieve both local control and elimination of potential micro metastases. Whereas there is evidence that surgery can cure localized prostate cancer, there are no clinical trials of multi-modal treatment of locally advanced prostate cancer that includes surgical removal of the prostate.
One potential advantage of adding prostatectomy to the treatment of LAPC is that removing the prostate enables a full pathological assessment of the tumor characteristics and thus a better estimation of the risk of recurrence. Surgical treatment could thus reduce the numbers needed to treat with chemotherapy and radiation, and thus improve quality of life after treatment. In addition, evidence indicate that residual cancer in the prostate occurs in 25% after radiation treatment (56) and surgical removal of the prostate may improve survival beyond what can be achieved by radiation and ADT. On the other hand, patients treated with surgery, radiation and hormones will experience side effects of all three treatment modalities and might fare better if radiotherapy plus hormones can provide oncological control without prior surgery.
A randomized clinical trial comparing two multimodal treatment regimens of which one includes a radical prostatectomy is therefore warranted.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostatic Neoplasms
Keywords
Prostatic neoplasms, Locally advanced, Radiotherapy, Surgery, Mortality
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Prostatectomy/Surgery
Arm Type
Experimental
Arm Description
Patients with locally advanced prostate adenocarcinoma recieves Prostatectomy/Surgery with or without adjuvant or salvage radiotherapy
Arm Title
Radiotherapy with adjuvant androgen deprivation therapy
Arm Type
Active Comparator
Arm Description
Patients with locally advanced prostate adenocarcinoma treated with adjuvant androgen deprivation therapy
Intervention Type
Procedure
Intervention Name(s)
Prostatectomy/Surgery
Intervention Description
Radical prostatectomy with or without adjuvant or salvage radiotherapy
Intervention Type
Other
Intervention Name(s)
Radiotherapy with adjuvant androgen deprivation therapy
Intervention Description
Radiotherapy with adjuvant androgen deprivation therapy
Primary Outcome Measure Information:
Title
Cause specific survival
Description
Cause-specific survival (CSS) will be calculated as "1-cause specific mortality. Mortality and mortality causes will be ascertained from the nationwide Cause-of-Death Register. In the absence of a functioning Cause-of-Death register, an endpoint committee of at least 2 medical doctors will determine the cause of death.
Time Frame
Up to 10 years
Secondary Outcome Measure Information:
Title
Metastasis free survival
Description
Composite endpoint of time to metastasis and survival
Time Frame
Up to 10 years
Title
Quality of life - general psychological, urinary, bowel and sexual health
Description
Questionnaire-based evaluation of general psychological health, urinary health, bowel health, and sexual health.
Questions about self Questions about quality of life in the past month (scale 1 to 7; 1=no quality, 7=the best quality) Depression and anxiety (scale 1 to 7; 1=no, 7=very) Symptom Form (EPIC-26) (scale 1 to 5; 1= no problem, 5=major problem) Questions about the urinary tract Questions about sexual function Questions about bowel function Questions about prostate cancer - diagnosis and treatment Questions about prostate cancer check-ups Questions about hormone/castration therapy and its significance Questions about pain and lymph swelling
Time Frame
At 1,2,5 and 10 years after randomization
Title
Overall survival
Description
Overall survival (OS) will be calculated as "1-overall mortality. Mortality data will be ascertained through the nationwide Cause-of-Death Register.
Time Frame
Up to 10 years
Title
Time to castration-resistant prostate cancer
Description
Ascertained at follow-up visits
Time Frame
Up to 10 years
Title
Time to biochemical progression
Description
Ascertained at follow-up visits
Time Frame
Up to 10 years
Title
Adverse events
Description
Ascertained at visits
Time Frame
Up to 10 years
Title
Cardiovascular disease
Description
Data from national PcBaSe-register (https://snd.gu.se/en/catalogue/study/ext0014), a registry where the national prostate cancer registry (NPCR, www.npcr.se) has been linked to the Swedish National Cancer Register, the Cause of Death Register, the Prescribed Drug Register, the National Patient Register, and the Acute Myocardial Infarction Register, the Register of the Total Population, the Longitudinal Integration database for health insurance and labour market studies (LISA), the Multi-Generatioon Register and several other population-based registers.
Time Frame
Up to 10 years
Other Pre-specified Outcome Measures:
Title
Health-care consumption
Description
Annual Defined Daily Dose (DDD) of analgesics, prescription databases
Time Frame
Annually up to 10 years
Title
Health-care consumption
Description
Annual number of days of hospitalization from patient registers
Time Frame
Annually up to 10 years
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≤75, at the time of randomization
Diagnosed histopathologically confirmed and untreated prostatic adenocarcinoma
The general condition and mental status of patients shall permit observation in accordance with the study protocol
Tumor stage (T, M, N):
T3 stage (as indicated by digital rectal examination or MR imaging or other validated imaging technique) T4 tumors can be included if considered resectable/treatable on MR imaging Significant extra-capsular tumor extension in biopsy (rare but acceptable for inclusion) M0 (no sign of distant metastases) confirmed by bone scan or CT or MRT of axial skeleton (at a maximum of pelvis and lumbar vertebral column) N0 stage, defined in accordance to the RECIST guidelines as no sign of macroscopic retroperitoneal lymph-node metastases >=1.5 cm (short axis) on CT scan, PET-CT, or MRT or more than one suspected lymph-node metastases Presence Gleason grade pattern 4 or 5
- Signed Informed consent
Exclusion Criteria:
Patients with a PSA value of > 100 ng/mL
Any medical condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives Patients with contraindications for either prostatectomy or radiotherapy to the prostate are not eligible for the study. Most contraindications for these treatments are relative, but in general, radiotherapy may be precluded among patients with:
Anorectal disease, such as fistulae, Crohn´s disease, and ulcerative colitis
Significant obstructive lower urinary tract symptoms
Proximal stricture of the urethrae
Severe neurogenic bladder dysfunction
Enlarged prostate beyond 70-90 ml
Previous radiotherapy to the pelvic region
On the other hand, surgery may be precluded among patients with:
Massive local tumor progression, particularly in the apical region
Massive abdominal obesity
Contraindications to anesthesia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Olof Akre, Prof.
Phone
+46-8-517 700 00
Email
olof.akre@ki.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Johan Stranne, M.D ass prof
Organizational Affiliation
Sahlgrenska University Hospital, Department of Urology, SE- 413 45 Gothenburg
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Camilla Thellenberg Karlsson, MD, PhD
Organizational Affiliation
Umeå University Hospital, Department of Radiation Science, SE-901 87 Umeå Sweden
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eva M Johansson, R.N PhD
Organizational Affiliation
Karolinska Institute, Nobelsväg, SE- 171 77 Solna, Sweden
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gunnar Steineck, M.D Prof
Organizational Affiliation
Karolinska Institute, Nobelsväg, SE-171 77 Solna, Sweden
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Klaus Brasso, M.D
Organizational Affiliation
Rigshospitalet, department Urology, DK-2001-Copenhagen, Denmark
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Peter M Meidahl Petersen, M.D ass prof
Organizational Affiliation
Rigshospitalet, Region h, Department of Oncology, Blegdamsvej 9, DK- 2001, Copenhagen, Denmark
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bjørn Brennhovd, M.D ass.prof
Organizational Affiliation
Oslo University Hospital, Department of Urology, P.O Box 4950 Nydalen, N-0424, Oslo Norway
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Wolfgang Lilleby, M.D ass.prof
Organizational Affiliation
Oslo University Hospital, Department of Radiation Therapy, P.O Box 4950, N-0424, Nydalen Oslo, Norway
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Antti Rannikko, M.D ass.prof
Organizational Affiliation
Helsinki University Central Hospital, Department Urology,Stenbäckinkatu 9, FIN-00290 Helsinki , Finland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mauri Kouri, M.D PhD
Organizational Affiliation
Helsinki University Central Hospital, Department Urology,Stenbäckinkatu 9, FIN-00290 Helsinki , Finland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tuomas Mirtti, M.D PhD
Organizational Affiliation
Helsinki University Central Hospital, Department Urology,Stenbäckinkatu 9, FIN-00290 Helsinki , Finland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aalborg University Hospital
City
Aalborg
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Niels Harving, M.D.
First Name & Middle Initial & Last Name & Degree
Niels Harving, M.D.
First Name & Middle Initial & Last Name & Degree
Mette Moe Kempel, M.D.
Facility Name
Aarhus University Hospital
City
Aarhus
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lise Bentzen, M.D.
First Name & Middle Initial & Last Name & Degree
Lise Bentzen, M.D.
First Name & Middle Initial & Last Name & Degree
Martin Mortensen, M.D.
Facility Name
Rigshospitalet, Region h, Department Oncology
City
Copenhagen
ZIP/Postal Code
DK-2001
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter M Meidahl Petersen, M.D ass
First Name & Middle Initial & Last Name & Degree
Peter M Meidahl Petersen, M.D ass prof
Facility Name
Rigshopsitalet Department urology
City
Copenhagen
ZIP/Postal Code
SE- 2001
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Klaus Brasso, M.D
First Name & Middle Initial & Last Name & Degree
Klaus Brasso, M.D
Facility Name
Herlev Hospital
City
Herlev
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henrik Jacobsen, M.D.
First Name & Middle Initial & Last Name & Degree
Henrik Jacobsen, M.D.
First Name & Middle Initial & Last Name & Degree
Henriette Lindberg, M.D.
Facility Name
Odense University Hospital
City
Odense
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steinbjørn Hansen, M.D.
First Name & Middle Initial & Last Name & Degree
Steinbjørn Hansen, M.D.
First Name & Middle Initial & Last Name & Degree
Mads Hvid, M.D.
First Name & Middle Initial & Last Name & Degree
Lars Lund, M.D.
Facility Name
Helsinki University Hospital, Department of Urology
City
Helsinki
ZIP/Postal Code
FIN-00290
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antti Rannikko, M.D ass prof
First Name & Middle Initial & Last Name & Degree
Antti Rannikko, M.D ass prof
First Name & Middle Initial & Last Name & Degree
Mauri Kouri, M.D PhD
First Name & Middle Initial & Last Name & Degree
Tuomas Mirtti, M.D PhD
Facility Name
Tampere University Hospital, Pihlajalinna Koskiklinikka
City
Tampere
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Teuvo Tammela, M.D.
First Name & Middle Initial & Last Name & Degree
Teuvo Tammela, M.D.
First Name & Middle Initial & Last Name & Degree
Teemu Murtola, M.D.
First Name & Middle Initial & Last Name & Degree
Petri Reinikainen, M.D.
Facility Name
Turku University Hospital
City
Turku
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Boström, M.D.
First Name & Middle Initial & Last Name & Degree
Peter Boström, M.D.
First Name & Middle Initial & Last Name & Degree
Kari Syvanen, M.D.
First Name & Middle Initial & Last Name & Degree
Paula Lindholm, M.D.
Facility Name
Sørlandet Hospital
City
Kristiansand
ZIP/Postal Code
4604
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christoph Müller, Ph.D. M.D.
First Name & Middle Initial & Last Name & Degree
Christoph Müller, Ph.D. M.D
First Name & Middle Initial & Last Name & Degree
Carl Hammarlund, M.D.
Facility Name
Oslo University Hospital, Department of radiation Therapy
City
Oslo
ZIP/Postal Code
N-0424
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wolfgang Lilleby, M.D ass prof
First Name & Middle Initial & Last Name & Degree
Wolfang Lilleby, M.D ass prof
Facility Name
Oslo University Hospital, Department Urology
City
Oslo
ZIP/Postal Code
N-0424
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bjorn Brennhovd, M.D ass prof
First Name & Middle Initial & Last Name & Degree
Bjorn Brennvold, M.D ass prof
Facility Name
University Hospital of North Norway
City
Tromsø
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hege Sagstuen, Ph.D.
First Name & Middle Initial & Last Name & Degree
Hege Sagstuen, Ph.D. M.D.
First Name & Middle Initial & Last Name & Degree
Tore Knutsen, M.D.
First Name & Middle Initial & Last Name & Degree
Bård Soltun, M.D.
First Name & Middle Initial & Last Name & Degree
Kari Margrethe Larsen, M.D.
Facility Name
St. Olavs Hospital
City
Trondheim
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Torgrim Tandstad, Ph.D.
First Name & Middle Initial & Last Name & Degree
Torgrim Tandstad, M.D.
First Name & Middle Initial & Last Name & Degree
Heidi Knobel, M.D.
First Name & Middle Initial & Last Name & Degree
Kristin Toftaker Killingberg, M.D.
First Name & Middle Initial & Last Name & Degree
Arne Solberg, M.D.
Facility Name
Falu Lasarett
City
Falun
ZIP/Postal Code
SE 791 82
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hampus Nugin, MD
First Name & Middle Initial & Last Name & Degree
Hampus Nugin, MD
Facility Name
Sahlgrenska University Hospital
City
Göteborg
ZIP/Postal Code
SE-413 45
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Johan Stranne, ass prof
First Name & Middle Initial & Last Name & Degree
Johan Stranne, M.D ass prof
Facility Name
Helsingborgs Lasarett
City
Helsingborg
ZIP/Postal Code
SE 25187
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Konstantinos Lentaris, MD
First Name & Middle Initial & Last Name & Degree
Konstantinos Lentaris, MD
Facility Name
Länssjukhuset Ryhov
City
Jönköping
ZIP/Postal Code
SE 553 05
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anders Jonsson, MD
First Name & Middle Initial & Last Name & Degree
Anders Jonsson, MD
Facility Name
Kirurgkliniken, Blekingesjukhuset
City
Karlskrona
ZIP/Postal Code
371 41
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amer Mousa Kadhem, M.D.
Phone
+46 455 73 10 00
First Name & Middle Initial & Last Name & Degree
Amer Mousa Kadhem, M.D.
Facility Name
Linköping University Hospital
City
Linköping
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Per Skoglund, M.D.
First Name & Middle Initial & Last Name & Degree
Per Skoglund, M.D.
First Name & Middle Initial & Last Name & Degree
Måns Agrup, M.D.
Facility Name
Skåne University Hospital
City
Malmö
ZIP/Postal Code
SE 205 02
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anders Bjartell, MD
First Name & Middle Initial & Last Name & Degree
Anders Bjartell, MD
Facility Name
Vrinevis Hospital
City
Norrköping
ZIP/Postal Code
SE 601 82
Country
Sweden
Individual Site Status
Terminated
Facility Name
Karolinska University Hospital
City
Stockholm
ZIP/Postal Code
SE 171 76
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Olof Akre, Prof
First Name & Middle Initial & Last Name & Degree
Mats Olsson, MD
Facility Name
Capio St Göran Hospital
City
Stockholm
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lillemor Nygren, M.D.
First Name & Middle Initial & Last Name & Degree
Lillemor Nygren, M.D.
First Name & Middle Initial & Last Name & Degree
Marie Hjelm-Eriksson, M.D.
Facility Name
Sundvalls Hospital
City
Sundsvall
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Johan Styrke, M.D.
First Name & Middle Initial & Last Name & Degree
Johan Styrke, M.D.
First Name & Middle Initial & Last Name & Degree
Lars Beckman, M.D.
Facility Name
Umeå University Hospital
City
Umeå
ZIP/Postal Code
SE 901 87
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Camilla Thellenberg, M.D PhD
First Name & Middle Initial & Last Name & Degree
Camilla Thellenberg, M.D PhD
Facility Name
Uppsala Akademiska Hospital
City
Uppsala
ZIP/Postal Code
SE 751 85
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eva Johanssson, M.D
First Name & Middle Initial & Last Name & Degree
Eva Johanssson, MD
Facility Name
Centrallasarettet
City
Växjö
ZIP/Postal Code
SE 352 34
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amer Elwaheidy, MD
First Name & Middle Initial & Last Name & Degree
Amer Elwaheidy, MD
Facility Name
Centrallasarettet Växjö Hospital
City
Växjö
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amer Elwaheidy, M.D.
First Name & Middle Initial & Last Name & Degree
Amer Elwaheidy, M.D.
Facility Name
Östersund Hospital
City
Östersund
ZIP/Postal Code
SE 831 31
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andreas Lundgren, MD
First Name & Middle Initial & Last Name & Degree
Andreas Lundgren, MD
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer
We'll reach out to this number within 24 hrs